The incorporation of these biomarkers, along with longitudinal serum NfL measurements and the correction for established confounders, has the potential to increase our understanding of the origin of axonal damage in peripheral neuropathies and may ultimately lead to better prognostic models. This evidence concerns the gene NEFL and peripheral neuropathy.